C-CZACCerevance
NETSseq, CNS therapeutics, cell type-specific therapies
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-CZAC
C-CZACC-CZACNETSseq, CNS therapeutics, cell type-specific therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.
This is a Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension and Tablet Formulations in Healthy Volunteers Under Fasted and Fed Conditions.
Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766 in Healthy participants.
This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.
This is a phase 1, double-blind, placebo-controlled, 3 period cross-over study to evaluate CVN058 target engagement by measuring auditory evoked potential mismatch negativity (MMN) downstream to 5-hydroxytryptamine receptor 3 (5-HT3) as a pharmacodynamic (PD) marker.
This is a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose ascending study in healthy subjects.
Takeda retains UK investment with new neuroscience company Cerevance | pharmaphorum Skip to main content Friday 26 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Resea
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline | Cerevance LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t
Privacy Policy About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Last updated: June 19, 2023 Privacy Policy This website is Your privacy and the protection of your data is important to Cerevance, LLC and its subsidiary entities (“Cerevance”, “us” or “we”) and we recognize the responsibility you entrust in us when providing your personal information. This Privacy Policy explains how we handle and treat your data when you visit our website and engage with us, as further described below. The purpose of this Privacy Policy is to provide you with a clear explanation of what perso … ibility or liability for these policies. Please check these policies before you submit any personal data to these websites. 12. Contact us You may contact us by sending a message to: [email protected]. You may also mail us a message or inquiry at the following address: Cerevance, Inc. One Marina Park Drive, Suite 1410 Boston, MA 02210 USA Attention: Data Privacy Official 13. Changes to this Privacy Policy We may make changes to this Privacy Policy. To ensure that you are a … Website in the form of questions, requests, user information, and other. If you submit information to Cerevance through this Website (e.g., the “Contact Us” webpage, via email, forms and/or questionnaires), all such information may be processed and utilized by Cerevance in accordance with the Privacy Policy and consistent with applicable laws and regulations. Cerevance shall have all appropriate use for the information without compensation to the user or visitor who provided … your consent. Right to lodge a complaint with a supervisory authority: You may submit a complaint about our use of your personal data, or our response to your requests regarding your personal data. To do this, you may contact us or submit a complaint to the Supervisory Authority in your jurisdiction: https://edpb.europa.eu/about-edpb/about-edpb/members_en. Please note that some of these rights may be limited where we have an overriding interest or legal obligation to continu … bligation to continue to process the personal data, or where certain exemptions apply. In order to exercise your rights, please contact Cerevance in writing by one of the methods set out under “Contact Us” above. D. How does Cerevance protect personal data if transferred internationally? We may transfer your personal data to recipients outside of
%PDF-1.5 %���� 830 0 obj > endobj xref 830 17 0000000016 00000 n 0000002789 00000 n 0000002922 00000 n 0000003976 00000 n 0000004470 00000 n 0000004507 00000 n 0000005083 00000 n 0000005197 00000 n 0000005460 00000 n 0000007972 00000 n 0000019235 00000 n 0000021884 00000 n 0000028932 00000 n 0000028971 00000 n 0000615080 00000 n 0004138858 00000 n 0000000636 00000 n trailer ]/Prev 11289375>> startxref 0 %%EOF 846 0 obj >stream h��V}TS� �ݏ$7!�{C��H/�+�9 :u74B�`�@e �� �P������\@.��!@Oah;u[O˜ծ;�~o��=뙝����u� vj��㽹�������ޓ�}���z��}s 0P0$�Bl���$P��q~��2s��1 �6�����'�(�����F��c�ΘA���q�- … ��5k��yݭ���ǯg��^y�kEk�����l�D_p߶������7Dm����o꿻1m��l�{��Mś� n�L�l� >stream application/pdf Milner Therapeutics Institute_logo master_CMYK Adobe Illustrator 25.2 (Macintosh) 2021-04-08T11:40:42+01:00 2021-04-08T11:40:42+01:00 2021-04-08T11:40:42+01:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:b628ce50-1a3f-41b6-b1df-7b77f2618aba uuid:55fea168-0588-ca43-a6a5-f038305a3954 xmp.iid:e1710c6e-e1b7-40f9-bd6b-a08497063b17 xmp.did:e1710c6e-e1b7-40f9-bd6b-a08497063b17 … �j�7�Y�Z�W�!�(W���V�V>���m !�>��[d�h�٥�t�z1[��_SV�I���_k7��ej�r5�!�k�o�rFp��Cˠ �nKC��!�����?� ���ʀ��g���R��i�r?L� @� ���t[3/ �����q1c2 ����oL����y���o� '�gO��.ln}]������N�t�i�M�fj�駊�s�g�t���� d_��6���K������c��g�z���ޯ�{��7����{z���=w^,�︉����}wN�����>���y��/!䇘l]_v�ꋾ_~�S��C&��X����3�����b��د��+� �O�ԥ�M�(���"�fӐ�H�-K�e��?��F��(��-��- ؕe�K%P��hjZ��!�RV$[����pp�}�sg�pf�����> ������?�x"@�1�}��\��yG��]���ҡ\������?y+��>��_.y��x��?9 … ����Zõ>\tl���X(D��4b�!�D`�\B�$6Q�)ܔ��a ��+�����e�n(5 I�e� �P蓔R�n��#��.pb��RfP"p�n*Q���E4�)D � ]� TSB�0���As��MBQA\�(���"� DW !0�� �4�,�y��b�ʗR(U�� �OPj�8�Õ�v��LM���* =�5"��S� �e�MC�wǺ�풎�Id��ی��W�o�$����O�ӡI�G��S��"ֱ�9���q|]O� �f߶2���ƙ�Ĵɷ�O���Z/���И XI.ߋ��l�;{D��E���f�8������ ����i;�2=.�i��9�`�I6Jnʒ؋�9K� ��#8�$���.���踻9�?�C ӌ�������¦bGd���ݸ�=h��I��:��� ����=>~H6��c��;�N2��Q�Ե�I�S�^jH7�Y1V��s{ۢXe���B�^#�r� =BZ7uN� T�1��wu�D��T��ܧ … ���+ [^�ְ���Diiד�[�������|����V_���n�q-�+.��@�{�,��薷2i� 0�[��Gu�߮�B1�`�>��S�~Rfp�65c�=p'//��ķ���qQmm�Q7�}��Fu��b.H�AQq+�"r�ѧc��u\x�$|[ jI����]����܅��Ŝ�Js^fD&�QofK���K���o�3�[��1H�u)6�C�v0P�v��j��D�g�� �z�q' "�.c}Ӎ�Ϲ�G�Ҩ�d"��IV"��^pv$��+e 쇴D/zX�*��b6�~yk���D� �>�$u��ȋ������o���hmZ��\;�D(�N;^�cՇK ��S/����2Kb�xތ
%PDF-1.6 %���� 41840 0 obj > endobj 41863 0 obj >/Filter/FlateDecode/ID[ ]/Index[41840 36]/Info 41839 0 R/Length 115/Prev 2042475/Root 41841 0 R/Size 41876/Type/XRef/W[1 3 1]>>stream h�bbd```b``�� �@$S5XDD2���`Y�} �� ��b��'����jԀ$��p�H+� b�7�H G�� R� lr"HMH�߳ L� ���]��H&��!~�7���c endstream endobj startxref 0 %%EOF 41875 0 obj >stream h�b```�� �@җA���X��c���T&��i�� aN�~(Gr `J �Y#��ÈI�`��r� �_@���z�&��8�B�;����hrT6�L����SBo��CNw���&�H�(�x��"*8ÙLz�q�� �{0�E��!&_�Y/��r w�}лG�%g�S�@��^�EL� �ETVp� >/Metadata 673 0 R/PageLayout/OneColumn/Pages 41807 0 R/StructTreeR … �l\�Y_K���S�� �r+�'5`E�i�}Vt�j���9 ��93���-�*����rN�E�)&���tl�`w��9qlx���$rfP���^����|�}� ��>� �3�dž��$��30��\'�ze=W���(�OF�/��c��q s���?g,ɟ��E�g�L18�(����8&pvd��cN ^;���O� y�N`�bpRXt %݇E�QL�̼�3t��8C��O�yJ&0s�����(�>,��� Lw��Ӝ���I��yJ&0s����0�>*�� ���9� ̜�$r���c2�����݇I�q�}pL�;o�� ��͒7��1w͟�����b@RRt $�'E��1�o���4'�7��$rF{�O&�s����F�}Rt�8&�7���2do`�I�����j�] endstream endobj 529 0 obj >stream hތW��\7 }/�E�X�!PH��R>�� �tQ��T����j�l … 457686-005c-499b-acd6-ffd3f7e43af1 uuid:d5c954ed-4e63-4120-9c4e-4fee49bb2d27 68 application/pdf Nicole Reisinger Adobe PDF Library 20.9.95 D:20200507 D:20200514 0x010100307CA6F60A88184B9EB3E10E019544DC endstream endobj 674 0 obj >stream hޜ��n1�_��`�����\8r�"n�C$"� � �U���ha|����s��*w����]��M��7�A,A��CY��\RC5J�XM�96KI��H���J3|��� U-tY}H��i��Ӑ.�i �(� �D�aX�a�e�� �ˆ)�ley���8���4fsS ���,�G1���$u��?�F9���>���8��������_�^{�zz����G,m�G�U����T���>�>���|zx���r��� … 457686-005c-499b-acd6-ffd3f7e43af1 uuid:197d980b-d491-4ad6-9ce6-c98f78fcfff2 68 application/pdf Nicole Reisinger Adobe PDF Library 20.9.95 D:20200507 D:20200514 0x010100307CA6F60A88184B9EB3E10E019544DC endstream endobj 41842 0 obj >/Font >/ProcSet[/PDF/Text/ImageC]/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 41876 0 obj > endobj 41877 0 obj >stream H���mo����S�B �VK.�@� ���; ���"+���JJ.�� �W�Ȍ�&H$�,9�?��ο� 6���C������a��Y_ ��C����l���P� �����jQ� … 457686-005c-499b-acd6-ffd3f7e43af1 uuid:38a70a0c-3e84-4398-a1b1-6e1d89d8496a 68 application/pdf Nicole Reisinger Adobe PDF Library 20.9.95 D:20200507 D:20200514 0x010100307CA6F60A88184B9EB3E10E019544DC endstream endobj 41842 0 obj >/Font >/ProcSet[/PDF/Text/ImageC]/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 41887 0 obj > endob
Biogen Acquires Apellis Pharmaceuticals for $5.6B, Adding EMPAVELI and SYFOVRE | Jack Shuang Hou posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to
Job Submit Success Congrats! Step one towards joining the Cerevance team is complete. We will contact you if you look like a good fit for the position you applied for. Thank you for your submission. on social media: MENU Home About Pipeline NETSseq Careers RESOURCES News Events Publications ASCEND Study ARISE Study INFORMATION Terms of Use Privacy Policy Cookie Preferences Copyright © Cerevance. All rights reserved. News Events Current May 12, 2026 Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 20 … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Cerevance Announces Presentation at AD/PD™ 2024 International Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Cerevance Announces Presentation at AD/PD™ 2024 International Conference February 27, 2024 | 2 min read Twitter LinkedIn Facebook Email Print Cerevance today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and re … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 May 12, 2026 | 5 min read Twitter LinkedIn Facebook Email Print Phase 3 ARISE trial of solengepras, a potential first-in-class non-dopaminergic therapy, is … res, Lightstone Ventures, MQB Partners, SV Health Investors’ Dementia Discovery Fund, and UPMC, underscoring their continued commitment to the program. Proceeds are expected to fund the company's operations into mid-2027, supporting completion of the ARISE trial and continued advancement of Cerevance's pipeline. Solengepras is a potential first-in-class, once-daily oral therapy that works through a fundamentally different mechanism than existing Parkinson’s treatments. By tar … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Takeda and Cerevance Team Up to Take on GI Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Takeda and Cerevance Team Up to Take on GI Diseases December 18, 2019 | 2 min read | Alex Keown Twitter LinkedIn Facebook Email Print Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roo … earch team. “We’re thrilled by Takeda’s endorsement of NETSseq and eagerness to apply it to GI disorders,” said Brad Margus, chief executive officer of Cerevance said in a statement to BioSpace. “This is the first of several exciting pharma partnerships we’ll be forming to extend our unique platform to more CNS diseases than we can pursue by ourselves.” Gareth Hicks, head of the Gastrointestinal Drug Discovery Unit at Takeda, said the collaboration with Cerevance will allow r … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders December 17, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Multi-year research alliance will apply Cerevance’s NETSseq technology to GI disorders Dec. 17, 2019 13:30 UTC &nbs … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Job Trends Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster December 2, 2016 | 2 min read Twitter LinkedIn Facebook Email Print December 2, 2016 By Mark Terry , BioSpace.com Breaking News Staff Tokyo-based Takeda Pharmaceutical Company and Lightstone Ventures launched a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance to Participate in the TD Cowen Treatment Advancements in Obesity and Related Disorders Summit - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cerevance to Participate in the TD Cowen Treatment Advancements in Obesity and Related Disorders Summit November 18, 2025 | 2 min read Twitter LinkedIn Facebook Email Print BOSTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong Obesity Lilly’s tirzepatide will be biggest blockbuster ever, topping $70B by 2032: Evaluate … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance Appoints Sagar Vaidya, M.D. Ph.D., as Chief Medical Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cerevance Appoints Sagar Vaidya, M.D. Ph.D., as Chief Medical Officer August 12, 2024 | 4 min read Twitter LinkedIn Facebook Email Print BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Cerevance, a leading clinical-stage biopharmaceutical company focused on developing precision novel therapeutics for central ne … ts and mentoring medical students. Dr. Vaidya completed his Infectious Diseases fellowship at Massachusetts General Hospital, Internal Medicine/Pediatrics residency at Icahn School of Medicine at Mount Sinai Hospital, and received his M.D./Ph.D. degrees from David Geffen School of Medicine at UCLA. Dr. Vaidya has several patents related to gene therapy and enzyme replacement therapies and is extensively published in peer-reviewed literature. About Cerevance Cerevance is … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance to Present During the 6th Annual LSX World Congress USA - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Cerevance to Present During the 6th Annual LSX World Congress USA September 6, 2023 | 2 min read Twitter LinkedIn Facebook Email Print Cerevance today announced Craig Thompson, chief executive officer (CEO) and Johnna Simões, vice president, corporate development, will participate in panel discussions during th … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance to Present at the Needham Healthcare Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Release … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Cerevance to Present at the Needham Healthcare Conference April 10, 2023 | 1 min read Twitter LinkedIn Facebook Email Print Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 22nd Annual Needham Healthcare Conference, being held virtually April 17-2 … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases April 19, 2022 | 2 min read Twitter LinkedIn Facebook Email Print Cerevance, a private, clinical-stage drug discovery and development company focused on central nervo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account November 18, 2024 08:30 ET | Source: Cerevance Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s diseaseARISE will evaluate the efficacy of solengepras as an adjunctive... November 11, 2024 08:30 ET | Source: Cerevance
https://www.takeda.com/our-impact/our-stories/small-fish-big-mission-biodiversity-japan/ 2026-06-09T13:52:40Z always 0.5 https://www.takeda.com/newsroom/newsreleases/2025/filing-of-corporate-governance-report-to-the-tokyo-stock-exchange/ 2026-04-14T13:38:04Z always 0.5 https://www.takeda.com/cookie-policy/ 2026-04-14T13:37:44Z always 0.5 https://www.takeda.com/newsroom/newsreleases/2026/entyvio-phase-3-pediatric-data/ 2026-04-14T13:37:57Z always 0.5 https://www.takeda.com/_404/ 2026-06-09T13:52:40Z always 0.5 https://www.takeda.com/our-impact/our-stories/integrity-in-the-aftermath-of-a-histori … lways 0.5 https://www.takeda.com/science/open-innovation/neuroscience-challenge/application-form/ 2026-04-14T13:38:04Z always 0.5 https://www.takeda.com/newsroom/newsreleases/2024/takeda-announces-the-pricing-terms-of-the-previously-announced-cash-tender-offers-for-certain-outstanding-notes/ 2026-04-14T13:38:04Z always 0.5 https://www.takeda.com/newsroom/statements/2025/inadvertent-abstract-disclosure-with-attachment/ 2026-04-14T13:37:57Z always 0.5 https://www.takeda.com/new … 26-06-24T08:35:52Z always 0.5 https://www.takeda.com/newsroom/newsreleases/2026/application-intravenous-entyvio-pediatric/ 2026-06-09T20:30:12Z always 0.5 https://www.takeda.com/about/corporate-responsibility/corporate-giving/programs/seed/ 2026-04-14T13:37:44Z always 0.5 https://www.takeda.com/our-impact/our-stories/how-digitalization-enables-sustainable-manufacturing/ 2026-04-14T13:37:57Z always 0.5 https://www.takeda.com/our-impact/our-stories/diversifying-psoriasis-trials … es/2023/continuation-of-the-stock-compensation-plan-for-directors-and-the-stock-grant-system-for-company-management-in-japan-in-2023/ 2026-04-14T13:37:44Z always 0.5 https://www.takeda.com/newsroom/newsreleases/2023/takeda-announces-results-from-phase-4-vedolizumab-study/ 2026-04-14T13:37:44Z always 0.5 https://www.takeda.com/newsroom/newsreleases/2023/takeda-awarded-2023-ipse-facility-of-the-year-award/ 2026-04-14T13:37:44Z always 0.5 https://www.takeda.com/newsroom/newsrele … wsreleases/2026/continuation-of-stock-compensation-plan-for-directors-and-stock-grant-system-for-company-management-in-japan-2026/ 2026-05-13T07:00:18Z always 0.5 https://www.takeda.com/newsroom/newsreleases/2026/takeda-reports-fourth-quarter-fy2025-results/ 2026-05-13T06:31:51Z always 0.5 https://www.takeda.com/our-impact/our-stories/mexico-pati
Episode 170 - Craig Thompson -… ‑ The BioHub - by Avetix ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 11 mai 29 min Episode 170 - Craig Thompson - CEO at Cerevance The BioHub - by Avetix Lire In this episode of The BioHub Podcast, Ben is joined by Craig Thompson, CEO of Cerevance. Craig has spent over three decades across biotech and pharma, leading companies through major stages of growth, development and strategic transformation. Today, he leads Cerevance, a clinical-stage neuroscience company focused on developing new medicines for neurological and neuropsychiatric
tak-20220331 0001395064 2022 FY false 33.33 33.33 33.33 33.33 33.33 33.33 2 0001395064 2021-04-01 2022-03-31 0001395064 dei:BusinessContactMember 2021-04-01 2022-03-31 0001395064 exch:XNYS 2021-04-01 2022-03-31 0001395064 tak:A0750SeniorNotesDue2027Member exch:XNYS 2021-04-01 2022-03-31 0001395064 tak:A1000SeniorNotesDue2029Member exch:XNYS 2021-04-01 2022-03-31 0001395064 exch:XNYS tak:A1375SeniorNotesDue2032Member 2021-04-01 2022-03-31 0001395064 tak:A2000SeniorNotesDue2040Member exch:XNYS 2021-04-01 2022-03-31 0001395064 tak:ADSMember 2022-03-31 xbrli:shares 0001395064 ifrs-full:OrdinarySha … eding 12 months (or for such shorter period that the registrant was required to submit such files).      Yes   ý      No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12 … ys in completing formulation and other testing and work necessary to support an application for regulatory approval; insufficient clinical trial data to support the safety or efficacy of the product candidate; difficulties in maintaining supply chains in investigational new drugs or commercial products; failure to bring a product to market prior to a competitor, or to develop a product sufficiently differentiated from a competing product to achieve significant market share; d … 21, the FDA issued a complete response letter (CRL) in response to our New Drug Application for TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis in which the FDA declined to approve the application and recommended an additional clinical study. Following receipt of the CRL, we decided not to pursue further development for TAK-721. Additionally, products approved for use and successfully marketed in one market may be unable to obtain regulatory … ry authority. Relevant health authorities may, at the time of the filing of the application for a marketing authorization, or later during their review, impose requirements that can evolve over time, including requiring additional clinical trials, and such authorities may delay or refuse to grant approval. Even where we have obtained marketing ap
%PDF-1.5 %���� 74 0 obj > endobj 77 0 obj > stream H���yTSw�oɞ����c [���5la� QIBH�ADED���2�mtFOE�.�c��}���0��8��8G�Ng��� ��9�w���߽����'����0 �֠�J��b� 2y�.-;!���K�Z� ���^�i�"L��0���-�� @8(��r�;q��7�L��y��&�Q��q�4�j���|�9�� �V��)g�B�0�i�W��8#�8wթ��8_�٥ʨQ����Q�j@�&�A)/��g�>'K���t�;\�� ӥ$պF�ZUn��� �(4T�%)뫔�0C&�����Z��i���8��bx��E���B �;�����P���ӓ̹�A� om?�W= �x������-�����[���0� ���}��y)7ta�����>j���T�7���@���tܛ�`q�2��ʀ��&���6�Z�L�Ą? �_ ��yxg)˔z���çL�U���*�u�Sk�Se�O4?�c����.�� ��R� ߁��-��2�5������ ��S�>ӣV����d�`r��n~��Y�&�+`��;�A4��
You need to enable JavaScript to run this app. Loading...
Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders | News & Events | Goodwin Skip to main content Goodwin Expertise People Careers Legal Paralegal Science Advisor Global Operations Team Insights & Resources About Us Our Story The Goodwin Way Opportunity, Inclusion, and Belonging Pro Bono Firm Leadership Locations News & Events Alumni Press Release December 20, 2019 Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders Professionals Noelle C. Dubiansky Shannyn Henke View … va Launches AHZANTIVE® Aflibercept Biosimilar in Europe Alert June 22, 2026 SEC Proposal Could Eliminate Baby Shelf Restrictions and Expand ATM Program Access For Smaller Companies Alert June 18, 2026 Delaware is Enforcing Its Principal Place of Business Requirement: An Inaccurate Address Can Block Good Standing Certificates Insight June 18, 2026 Royalty Monetization in an Era of Drug Pricing Pressure: How the IRA is Affecting Royalty Monetizations Big Molecule Watch June 16,
Careers About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Personal. Collective. – Join Us – CURRENT OPENINGS Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere. No items found. on social media: MENU Home About Pipeline NETSseq Careers RESOURCES News Events Publications ASCEND Study ARISE Study INFORMATION Terms of U … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
13th Annual Outsourcing in Clinical Trials Southern California 2025 - Arena International --> Home About Us Events Contact Us Why attend? Agenda OCT Advisory Board Speakers Plan Your Visit Event Gallery Sponsors Why partner? Resources Contact Us Download Agenda Registration Closed 13th Annual Outsourcing in Clinical Trials Southern California 2025 Creating a collaborative environment where pharma & biotech leaders can find solutions to current challenges through innovations and partnerships Start 23 Sep End 24 Sep Hyatt Regency La Jolla at Aventine, San Diego, USA Reg … University of Texas School of Public Health. He completed an Internal Medicine residency and fellowship and joined the faculty as Assistant Professor of Medicine. Dr. Lewis has dedicated his professional career to patient care, teaching, clinical research, and drug development. His areas of interest are infectious disease, oncology, and metabolic disorders. He has participated as an Investigator on over 30 clinical trials and authored over 50 scientific abstracts and publica … ved as a CIRM CAR-T cell principal investigator, NIH / NCI study section, CPRIT grant review panel, biotechnology and pharmaceutical advisory boards, IRB/SRC, and scientific journal editorial review committees related to cancer and gene therapy, as well as authoring numerous scientific papers and patent applications. Next speaker Back Anne Severtson Senior Director, Clinical Operations, AnaptysBio I am a clinical research operations specialist with two decades of experience … breakthroughs across the globe by delivering custom-built research services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. We are passionate about our work, creating value for patients and customers while generating opportunities for employees to thrive. Company Website To learn more, please visit … han 110 countries. Together, we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit SyneosHealth.com. Company Website To learn more, please visit our website - www.Syneo
%PDF-1.4 %���� 596 0 obj 3684 endobj 599 0 obj > /AP > /F 4 /Subtype /Link >> endobj 598 0 obj > /AP > /F 4 /Subtype /Link >> endobj 593 0 obj 4057 endobj 592 0 obj > stream x��[�r��EߘT��S�Tp�w��&����H��a� �k�+Kٟ�J�ߗ��tc����C*f��.3ӷ���w"���;[���O�@dq����r�����eQ���_�j?�0N�'E�g�_��? g ,������?ВJQD�H�_G1��jM��6�I�2� L$\�a�>��I�E.����li1#��P*-�~VDҝ�Q�F�f�.�� ��e �,ڥo�_k�3���̏���$t�j3E�f�5]�z;��`�l?�œ"�����n"�P��e����Q=� ��ݚf����2�{1ʹ2�#JO�E�ӎ��,��Z��"��g{���V9�_�n��p-����(a�����K�(l��4b܅b��~����$ w9�^�ŽE7:ߡ� P�a5���Z0!��1�32�f�3~��02f���� 5m��Yf���
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Cerevance starts dosing in Phase I clinical trial of CVN424 for treatment of Parkinson's disease Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatolog … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Neuroscience research questions traditional markers for cerebellar movement disorders
9th GPCRs in Medicinal Chemistry - RSC BMCS --> Home About Us Committee News Events 9th RSC-CICAG / RSC-BMCS Artificial Intelligence in Chemistry RSC-BMCS 10th Fragment-based Drug Discovery 10th RSC-BMCS/RSC-SCI GPCRs in Medicinal Chemistry RSC-BMCS/SCI Targeted Protein Degradation 2026 BMCS Hot Topics: AI in Drug Discovery 2026 BMCS Antibody-Drug Conjugates 2026 20th Postgraduate Symposium BMCS New Approaches to Neurodegenerative Diseases 9th RSC/SCI Ion Channels as Therapeutic Targets 11th RSC-BMCS Symposium on Mastering Medicinal Chemistry BMCS Event archive Event archive from Maggi Churcho … e Awards BMCS Hall of Fame and Medal BMCS Lectureship Malcolm Campbell Memorial Prize Capps Green Zomaya Award Grants Bursaries International Travel Prize Researcher Mobility Fellowship Education Support Enhanced Equipment Chemistry Clubs Partnership of 3 Undergraduate Chemical Societies Funding from RSC Local Sections Contact Us Home About Us Committee News Events 9th RSC-CICAG / RSC-BMCS Artificial Intelligence in Chemistry RSC-BMCS 10th Fragment-based Drug Discovery 10th R … e Awards BMCS Hall of Fame and Medal BMCS Lectureship Malcolm Campbell Memorial Prize Capps Green Zomaya Award Grants Bursaries International Travel Prize Researcher Mobility Fellowship Education Support Enhanced Equipment Chemistry Clubs Partnership of 3 Undergraduate Chemical Societies Funding from RSC Local Sections Contact Us Events 9th GPCRs in Medicinal Chemistry Charlotte Turpin 2024-09-26T09:29:28+00:00 9th GPCRs in Medicinal Chemistry Event 9th RSC-BMCS/RSC-SCI Sympo … on-Member- £395 * Member is a paid-up member of the RSC or SCI ** Student rates apply to undergraduate and post-graduate students only, but not post-doctoral students or students in full-time employment. Registration fees include: – coach transport between Verona city centre and the Evotec campus at the start and end of each day – dinner on Wednesday evening at Spiller Restaurant – vineyard visit and dinner on Thursday evening at Rocca Sveva. Networking Social Activities and … elegate handbook – your web-linked company name on this page – your logo in the rolling slides, shown during the breaks – full attendance at the technical programme, poster sessions, Wednesday evening dinner, and Thursday evening vineyard visit and dinner. Important further information about Evotec’s requirements for advance deliveries may be fou
Key Scientific and Clinical Insights Leading to Cerevance's Pursuit of Solengepras | PharmExec --> --> News News Academy Multimedia Editorial Podcasts Editorial Videos Peer Exchange Profiles in Medicine Shorts Conferences Conference Coverage Conference Listing More Publications Pharmaceutical Executive Partner Perspectives Resources Content Engagement Hubs E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers Subscribe My Account News Academy Multimedia Conferences Publications Partner Perspectives Resources Subscribe Corporate Communications Press Releases Executive Roundtab … turing By Mike Hollan , Kyle Smith June 22nd 2026 Additive Manufacturing's Application in Pharma and Biotech By Mike Hollan June 19th 2026 Redefining Obesity Success in the GLP-1 Era: Q&A with Brian Hilberdink By Nicholas Jacobus , Brian Hilberdink June 19th 2026 Advertisement Advertisement Trending on PharmExec 1 EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval 2 Reading Between the Lines: Closing the T1D Misdiagnosis Gap 3 Pharmaceutical Executive Daily: FDA
Cerevance Closes $45 Million Series B | News & Events | Goodwin Skip to main content Goodwin Expertise People Careers Legal Paralegal Science Advisor Global Operations Team Insights & Resources About Us Our Story The Goodwin Way Opportunity, Inclusion, and Belonging Pro Bono Firm Leadership Locations News & Events Alumni Press Release April 14, 2020 Cerevance Closes $45 Million Series B Professionals Kingsley L. Taft Noelle C. Dubiansky View PDF Share The Life Sciences team advised Cerevance on the closing of its $45 million Series B financing from new investors including GV (forme … previous investors, which include Takeda Ventures, Inc., the Dementia Discovery Fund and Lightstone Ventures. Cerevance will use the proceeds to continue identifying novel therapeutic targets for central nervous system diseases, such as Alzheimer’s disease, by transcriptionally and epigenetically profiling specific neuronal and glial cell populations in thousands of post-mortem human brain tissue samples and advancing a diverse portfolio of therapeutic programs against … va Launches AHZANTIVE® Aflibercept Biosimilar in Europe Alert June 22, 2026 SEC Proposal Could Eliminate Baby Shelf Restrictions and Expand ATM Program Access For Smaller Companies Alert June 18, 2026 Delaware is Enforcing Its Principal Place of Business Requirement: An Inaccurate Address Can Block Good Standing Certificates Insight June 18, 2026 Royalty Monetization in an Era of Drug Pricing Pressure: How the IRA is Affecting Royalty Monetizations Big Molecule Watch June 16,
Sign Up Now - The Ascend Study | Cerevance LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cooki
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media September 25, 2018 Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any pa … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
NETSseq About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact NETSseq - Innovative Discoveries for CNS Disorders Landmark discoveries for CNS disorders NETSseq enables the identification of subtle molecular changes that can drive disease progression, offering a transformative tool to identify novel drug targets for CNS disorders. ( N uclear E nriched T ranscript S ort seq uencing) HUMAN DISEASE BIOLOGY Identify disease-relevant human brain regions and cell types. PURIFIED NUCLEI FROM KEY CELL TYPES NETSseq sorts nuclei from 60+ disease relevant cell types, including ultra-rare p … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
🖥️ Join us online on April 3 for... - Parkinson's Foundation Facebook Log In Parkinson's Foundation's Post Parkinson's Foundation Verified account March 25, 2024 · Shared with Public Join us online on April 3 for Parkinson's 101, sponsored by Cerevance! Dr. Leslie J. Cloud, from Virginia Commonwealth University Parkinson's and Movement Disorders Center, will provide a basic overview of Parkinson's disease, what causes it, common symptoms, treatments, and strategies for managing symptoms. Register for free: parkinson.org Parkinson's 101 All reactions: 20
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin … nested selector system. London and Boston, 3 May 2017 – The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. With locations in Boston, Massachusetts and Cambridge, UK, Cerevance is harnessing a proprietary technology platform, invented in the Howard … Alzheimer’s and Parkinson’s disease. “We are eager to see Cerevance immediately apply its powerful approach to dementia,” said Tetsuyuki Maruyama, Ph.D., Chief Scientific Officer of the Dementia Discovery Fund who will serve on Cerevance’s Board of Directors. “Our Scientific Advisory Board, which contains senior R&D leaders from seven global pharmaceutical and biotech companies, is confident that Cerevance will make breakthrough discoveries, enabling the company to advanc … ” said Laurence Barker, Ph.D., Chief Business Officer of the Dementia Discovery Fund. “With exceptional science, a strong sense of urgency, a leadership team that has previously succeeded together in drug discovery and solid investor support, Cerevance is well positioned to deliver lifechanging therapeutics for dementia patients.” “It is thrilling to welcome an investor whose strategic focus is so perfectly aligned with our mission,” said Brad Margus, Chief Executive Officer … he investment team and strategic investors involved with the Dementia Discovery Fund will give Cerevance access to a dream team of world-class advisors.” Together with the $36 million in commitments of equity and non-dilutive capital from Lightstone Ventures and Takeda Pharmaceuticals Company, Ltd. (TSE: 4502) announced in December, the new compa
Media About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Cerevance Media Center A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine News Events publications Current News May 12, 2026 Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 Phase 3 ARISE trial of solengepras, a potential first-in-class non-dopaminergic therapy, is fully enrolled and topline data is expected at the end of Q3 2026 Pivotal study targets daily OFF periods, a debilitating unmet need affe … t Malenka, M.D., Ph.D., to Advise Cerevance 2017 May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia 2017 December 2, 2016 Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases 2016 No items found. April 9, 2026 Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting Solengepras, a once-daily, oral, non-dopami … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
LSX World Congress USA Skip to main content Speaking Engagement LSX World Congress USA Keep up with the latest legal and industry insights, news, and events from MoFo Sign Up Share menu Facebook Twitter Print LinkedIn 13 Sep 2023 - 14 Sep 2023 Hynes Convention Center 900 Boylston Street Boston, MA 02115 Morrison Foerster is proud to sponsor the LSX World Congress USA, September 13-14, 2023 in Boston, MA. During the two-day conference, the leading biotech, medtech, and healthtech executives, investors, and trusted advisors will convene for programming, partnering, and networking opportunities.
Media About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Cerevance Media Center A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine News Events publications Current News May 12, 2026 Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 Phase 3 ARISE trial of solengepras, a potential first-in-class non-dopaminergic therapy, is fully enrolled and topline data is expected at the end of Q3 2026 Pivotal study targets daily OFF periods, a debilitating unmet need affe … t Malenka, M.D., Ph.D., to Advise Cerevance 2017 May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia 2017 December 2, 2016 Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases 2016 No items found. April 9, 2026 Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting Solengepras, a once-daily, oral, non-dopami … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Cerevance Careers | Levels.fyi Download App Change Login Sign Up All Data By Location By Company By Title Salary Calculator Chart Visualizations Verified Salaries Internships H-1B Salaries Negotiation Support Compare Benefits Who's Hiring 2025 Pay Report Top Paying Companies Integrate Blog Press Google Software Engineer Product Manager New York City Area Data Scientist Explore By Different Titles Levels FYI Logo Salaries 📂 All Data 🌎 By Location 🏢 By Company 🖋 By Title 🏭️ By Industry 📍 Salary Heatmap 📈 Chart Visualizations 🔥 Real-time Percentiles 🎓 Internships 🛂 H-1B Salaries ❣️ … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Featured Jobs No featured jobs found for Cerevance Related Companies DoorDash SoFi Square Spotify Snap See all companies ➜ Other Resources End of Year Pay Report Calculate Total Comp Featured Jobs No featured jobs found for Cerevance Related Companies DoorDash SoFi Square Spotify Snap See all companies ➜ Other Resources End of Year Pay Report Calculate Total Comp Request an AI summary of Le
Pipeline About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Multiple CNS Therapies Advancing An advanced pipeline that’s closer to where you live than you might expect. Synaptic Modulation Neuroinflammation Neurometabolism cvn424 Parkinson's disease (Adjunctive & monotherapy) cvn766 Schizophrenia (Negative and cognitive symptoms) CVN293 ALS/Alzheimer's disease (Disease modification) CVN398 Parkinson's disease (Disease modification) Target-18 Parkinson's disease (Disease modification) Target-26 Alzheimer's disease ( Disease modification) Multiple E … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
solengepras (CVN424) / Cerevance solengepras (CVN424) / Cerevance - LARVOL DELTA Home Next Prev 1 to 25 Of 56 Go to page 1 2 3 June 19, 2026 Discovery of Small Molecule Ligands Targeting Orphan G Protein-Coupled Receptors GPR3, GPR6, and GPR12. (PubMed, J Med Chem) - "Notably, the GPR6 inverse agonist CVN424 is currently in Phase III clinical trials for the treatment of Parkinson's disease (PD)...Herein, we summarize the current understanding of the structural and functional characteristics of GPR3, GPR6, and GPR12. We further highlight recent progress in relevant ligand discovery and
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media October 8, 2024 Cerevance Achieves Second Milestone in Research Collaboration with Merck What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. F … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact RECENT NEWS: Phase 3 Parkinson's Disease Trial Fully Enrolled & Series C Closed The Up Close View of the Central Nervous System A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine Innovative Targets Selected Based on the Human Journey A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine “C” it for Yourself Robust pipeline with cell type-specific therapies Discover the NETSseq Platform NETSseq insights provide a deeper understanding of the complexities of the human … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Cerevance Establishes Strategic Research Collaboration With Merck - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & compliance Diversity and inclusion Policies and positions Suppliers Suppliers overview Supplier registration Suppli
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media February 21, 2018 Cerevance Kicks Off 2018 with Additional $10 Million of Infusions What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dy … first six weeks of 2018 totaling more than $10 million. The Dementia Discovery Fund, which previously invested in Cerevance in May and November of 2017, increased its ownership position by fifty percent, while Takeda Pharmaceuticals Company Limited made a payment to the company triggered by Cerevance achieving a key milestone in implementing its proprietary NETSseq target discovery platform. The company has now brought in over $43 million in cash since its inception in the e … sh since its inception in the end of 2016. Cerevance’s scientists have begun to apply the company’s unique molecular profiling capability to more than 3,000 human brain tissue samples that it has assembled and used its extensive data pipeline to analyze specific populations of neurons and glia across different disease states and ages. As it continues to aggressively scale its tissue access and discovery operations, the company expects to reveal therapeutic targets selectively … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
S-1/A 1 d564688ds1a.htm S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 14, 2018 Registration No. 333-227112 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARVINAS HOLDING COMPANY, LLC (to be converted into Arvinas, Inc.) (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Prima … ritical to successfully engineering PROTAC therapeutics with potentially robust application across multiple indications and therapeutic areas: potency, selectivity, and deliverability and versatility. We have harnessed these features to successfully target and degrade a wide range of protein classes, including nuclear proteins, transcription factors, epigenetic modulators, membrane proteins, cytosolic proteins and high molecular weight neuroprotein aggregates. 2 Table … dies intended to support the submission of an investigational new drug, or IND, application, including expanded toxicology, drug product optimization and IND documentation preparation. Our two lead product candidates are ARV-110 and ARV-471. We are developing ARV-110, a PROTAC targeting the androgen receptor protein, or AR, for the treatment of men with mCRPC. We expect to submit an IND to the U.S. Food and Drug Administration, or FDA, for ARV-110 in the 3 Table of Con … ER, for the treatment of women with metastatic ER+ breast cancer. We expect to submit an IND to the FDA for ARV-471 in the first half of 2019, initiate a Phase 1 trial in mid-2019 and receive preliminary clinical data in 2020. In our preclinical studies, these lead product candidates have demonstrated potent and selective protein degradation. We believe favorable clinical trial results in these initial oncology programs would provide validation of our platform as a new thera … our PROTAC platform to address undruggable targets. • Apply our PROTAC platform to develop new therapeutics with distinct advantages over existing modalities, including gene-based medicines. • Continue to expand the capabilities of our PROTAC platform and the breadth of our intellectual property
Media About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Cerevance Media Center A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine News Events publications Current News October 17, 2024 Sarah Sheikh Joins Cerevance’s Board of Directors Cerevance is pleased to appoint Sarah Isabel Sheikh, M.Sc., B.M. B.Ch., MRCP, to its Board of Directors, effective immediately. Dr. Sheikh holds dual responsibilities at Takeda as the Head of Global Development for all therapeutic areas – Gastrointestinal and Inflammation, Neuroscience, Oncology, Plasma-Derived Therapies, a … t Malenka, M.D., Ph.D., to Advise Cerevance 2017 May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia 2017 December 2, 2016 Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases 2016 No items found. April 9, 2026 Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting Solengepras, a once-daily, oral, non-dopami … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Cerevance becomes latest investment from UPMC Enterprises’ Translational Sciences team | UPMC Enterprises Menu About Overview Digital Solutions Technology Services Ahavi Translational Sciences Portfolio Team Our Team Careers Resources Insights News Center for Connected Medicine Contact Sep 28, 2020 Cerevance becomes latest investment from UPMC Enterprises’ Translational Sciences team Cerevance Share After announcing a $1 billion commitment to life sciences startups earlier this year, UPMC Enterprises’ Translational Sciences team makes second external investment. UPMC Enterprises’ Translational
Merck Returns to Alzheimer’s Disease with $1.1B Cerevance Pact - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Re … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Merck Returns to Alzheimer’s Disease with $1.1B Cerevance Pact August 9, 2022 | 4 min read | Alex Keown Twitter LinkedIn Facebook Email Print Courtesy of Tada Images/Getty Images Using Cerevance’s proprietary NNETSseq technology platform, Merck and Cerevance have partnered to ide … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Cerevance Website: Cerevance Business Area(s) Neurological Disease Small Molecules Parkinson's Disease Description Cerevance is developing therapeutics that act on target proteins expressed highly selectively in brain cell types that die in disease, play a key role in the disease process, or are
Foresite Capital --> --> Cerevance – Foresite Capital Strategy Portfolio People Careers News Blog Contact Us --> Back Portfolio Next Cerevance, a private, clinical-stage pharmaceutical company focused on brain diseases, is applying a new technology, called NETSseq, to reveal transcriptional and epigenetic differences between specific cell types in mature human brains. NETSseq profiles neuronal and glial cell populations at depths not possible with other approaches, generating unprecedented data sets and insights. The company has thus far partnered with 14 brain banks around the world to
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Merck swings back into Alzheimer's with $1.1bn Cerevance alliance | pharmaphorum Skip to main content Friday 26 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Res
Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories P … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia … harmaceutical Scale-Up Buy Reports Newsletters CT News Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy The Series B extension proceeds will fund Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease. Phalguni Deswal April 26, 2024 Share Copy Link Share on X Share on Linkedin Share on Facebook Cerevance’s CVN424 is a non-dopamine G protein-coupled receptor 6 (GPR6) inhibitor. Image Credit: Pla2na / Shutterstro … 5, as per ClinicalTrial.gov . In February, Cerevance raised $51m in Series B to fund the Phase II trial. The primary endpoint of the study is CVN424’s ability to improve Parkinson’s disease motor symptoms and the impact of those symptoms on activities of daily living. This is measured by Parts II and III of the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) after 12 weeks of administration. The trial is expected to inform the design for the P
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's dise
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
Cerevance, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Cerevance, Inc. Startups | Holding Company | 2016 | Massachusetts, United States | 50-100 | www.cerevance.com Startups | Holding Company | 2016 | Massachusetts, United States | 50-100 | www.cerevance.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Cerevance is a company that focuses on creating innovative therapies for severe neurologi … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media July 10, 2023 Cerevance to Present at the Alzheimers Association International Conference What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media July 11, 2025 Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Cerevance to Join Precision Neurotherapeutics Panel at 2024 BIO International Convention Products Data Feature Plans Request Demo Sign Up for Free Cerevance to Join Precision Neurotherapeutics Panel at 2024 BIO International Convention 28 June 2024 Cerevance , a company dedicated to the development of precise therapeutics for central nervous system (CNS) disorders, has announced that its CEO, Craig Thompson, will be part of a panel at the 2024 BIO International Convention in San Diego, CA. This convention will be held from June 3 to June 6, 2024. Craig Thompson will join the panel titled "Targ
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media June 8, 2022 Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any page and be … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media May 20, 2024 Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it int … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Get the job you really want - Zippia Verifying you are human. This may take a few seconds. (Loading widget...)
Missed Today’s Webinar? Watch... - Neuro Challenge Foundation Facebook Log In Neuro Challenge Foundation's Post Neuro Challenge Foundation October 29, 2025 · Shared with Public Missed Today’s Webinar? Watch It Now on YouTube! If you weren’t able to join us for “ARISE: A Clinical Trial to Test an Investigational Therapy for the Symptoms of Parkinson’s Disease” presented by Dr. Robert Hauser and Neuro Challenge Foundation for Parkinson’s, you can now watch the full presentation on YouTube! Watch now: https://youtu.be/eYTGmN0a73E In this informative session, Dr. Hauser discusses the ARISE st
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media October 18, 2023 Cerevance to Participate at the Leerink Biopharma Private Company Connect What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Bill Gates among investors as Cambridge Science Park-based Cerevance raises $45m to fight brain diseases Sign in Account SINCE 1819 ☰ Premium site Buy a photo | E-edition | Iliffe Media | About us | Advertise | Public Notices | Jobs | Announcements | Newsletter | Velvet Mag | Contact | | Subscribe to Premium Unlock unlimited access to all stories Home News News Cambridge Combined Authority Crime East Cambridgeshire East West Rail Environment Health Latest News Nostalgia Politics RSS Feeds South Cambridgeshire Videos Spotlight Sport Sport Football Cricket Shelford Rugby Club Cambridge Un … l of Cerevance’s previous investors joined in, including the Dementia Discovery Fund, Lightstone Ventures and Takeda Ventures Inc, the corporate venture arm of Takeda Pharmaceutical Company. Brad Margus, CEO of Cerevance, said: “It’s hard to imagine a more stellar group of investors supporting us. “We look forward to drawing on their expertise in deep data analysis and therapeutic development as we mine our unique biological data sets to advance new, desperately needed therap … “Cerevance has a differentiated approach to neurotherapeutics and continues to apply its powerful NETSseq platform to central nervous system diseases. “With exceptional science, a strong sense of urgency and a leadership team that has previously succeeded together in drug discovery, Cerevance is well-positioned to deliver life-changing therapeutics for patients with brain diseases.” The company has partnered with 14 brain banks around the world to assemble its growing collec
Cerevance Closes $45 Million Series B Financing --> Accessibility: Skip TopNav Cerevance Closes $45 Million Series B Financing Proceeds to Fund a Diverse Pipeline of Therapeutics Acting on Novel Targets for Brain Diseases April 14, 2020 10:17 ET | Source: Cerevance Cerevance BOSTON, MA, April 14, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s p … rate venture arm of Takeda Pharmaceutical Company, Ltd., the Dementia Discovery Fund and Lightstone Ventures. Cerevance will use the proceeds of the financing to continue identifying novel therapeutic targets for central nervous system diseases, such as Alzheimer’s disease, by transcriptionally and epigenetically profiling specific neuronal and glial cell populations in thousands of post-mortem human brain tissue samples and advancing a diverse portfolio of therapeutic progra … “Cerevance has a differentiated approach to neurotherapeutics and continues to apply its powerful NETSseq platform to central nervous system diseases,” said David Schenkein, M.D., General Partner at GV. “With exceptional science, a strong sense of urgency and a leadership team that has previously succeeded together in drug discovery, Cerevance is well-positioned to deliver life-changing therapeutics for patients with brain diseases.” “It’s hard to imagine a more stellar grou
Get the job you really want - Zippia Verifying you are human. This may take a few seconds. (Loading widget...)
Empowering innovators to improve patients' lives - SV Health Investors Strategy Therapeutics Healthcare Growth Medtech People Portfolio News Contact Investors SV8 Biotech Fund SV7+ Growth Fund Dementia Discovery Fund-2 SV Biotech Crossover Opportunities Fund SV7 Impact Medicine Fund SV7 Growth Fund Dementia Discovery Fund-1 SV Life Sciences Funds 5-6 SV Fund IV Continuation Fund SV Life Sciences Funds 3-4 Investing in tomorrow’s healthcare breakthroughs Therapeutics • Healthcare Growth • Medtech Therapeutics Seeking innovative breakthroughs with the power to change therapeutic paradigms H
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media August 9, 2022 Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static conten … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Jobs at Cerevance | GV You are using an outdated browser. Please upgrade your browser to improve your experience and security. About Team Portfolio News Social Close AI Mode Close Linkedin Instagram Facebook Youtube X Request an AI Summary Gemini ChatGpt Claude Grok perplexity ` About Team Portfolio News Social Linkedin Instagram Facebook Youtube X AI Mode Request an AI Summary Powered by Consider Privacy Terms Linkedin Instagram Facebook Youtube X Privacy Policy News Press Jobs © 2026 GV. All rights reserved.
Cerevance Nabs $45 Million in Funding to Support CNS Disease Research - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cerevance Nabs $45 Million in Funding to Support CNS Disease Research April 14, 2020 | 3 min read | Alex Keown Twitter LinkedIn Facebook Email Print Cerevance secured $45 million in a Series B financing round to support the development of its therapeutics for central nervous syst … rate venture arm of Takeda Pharmaceutical Company, Ltd., the Dementia Discovery Fund and Lightstone Ventures. In an interview with BioSpace, Margus said the investors in the Series B are those who appreciate data sets that could change the world. He said the company’s NETSseq technology is generating unprecedented data sets and they’re gaining insights into why some cell types are more vulnerable than other cell types. Those insights will be used to advance new and “desperate … “Cerevance has a differentiated approach to neurotherapeutics and continues to apply its powerful NETSseq platform to central nervous system diseases,” David Schenkein, General Partner at GV said in a statement. “With exceptional science, a strong sense of urgency and a leadership team that has previously succeeded together in drug discovery, Cerevance is well-positioned to deliver life-changing therapeutics for patients with brain diseases.” Earlier this year, Cerevance tea … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance Limited — Find UK Skilled Worker Visa Sponsors Visa Path UK Search Salary Checker CV Tool Jobs Councils Guides 🏛️ Civil Service Guide 🎓 Teaching Jobs Guide 🏥 Healthcare Jobs Guide About Coaching NHS Statement Pricing Find Sponsors → 🔍 Search 💷 Salary Checker 🎯 CV Tool 💼 Jobs 🏛️ Councils Guides 🏛️ Civil Service Guide 🎓 Teaching Jobs Guide 🏥 Healthcare Jobs Guide ℹ️ About 🎯 Coaching 📝 NHS Statement 💳 Pricing Find Sponsors → ← Back to results Cerevance Limited 📍 Cambridge, Nan ✓ Active CoS Sponsor Licence Type Worker (A rating) Data Updated 03/04/2026 📋 Certificate of Sp … or job alerts, a cover letter tool, and AI CV analysis — everything you need to apply faster and stronger. Upgrade — £9/month → Write my supporting statement — £1 Data sourced from the Home Office Register of Licensed Sponsors. Always verify current status at find-employer-sponsors.homeoffice.gov.uk before applying. VisaPath UK A verified Skilled Worker visa sponsor search platform. Data sourced directly from the Home Office register. Quick Links Search Sponsors Salary Checke
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media January 25, 2022 Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766 What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dy … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Leadership transition at Cerevance | The Pharmaletter Friday 26 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell An
Neurodegeneration breakthrough: GV, Bill Gates invest $45m in Cerevance Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patent … he venture arm of the Japanese pharma giant – as well as the Dementia Discovery Fund and Lightstone Ventures. Go deeper with GlobalData Reports Innovations in Pharma - Report Bundle (5 Reports) Reports Global Mergers and Acquisitions (M&A) Deals in the Healthcare S... Go deeper with GlobalData The gold standard of business intelligence. Find out more Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged professionals … rest in neurodegeneration through previous investment in the Dementia Discovery Fund. GV general partner David Schenkein stated: “Cerevance has a differentiated approach to neurotherapeutics and continues to apply its powerful NETSseq platform to central nervous system diseases. “With exceptional science, a strong sense of urgency and a leadership team that has previously succeeded together in drug discovery, Cerevance is well-positioned to deliver life-changing therapeutics
Terms of Use About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Last updated: June 2023 Terms of Use This website is owned and operated by Cerevance, LLC, a limited liability company with a business address of One Marina Park Drive, Suite 1410, Boston, MA 02210, United States, and its subsidiaries (collectively “Cerevance”, “we”, or “us”). These Terms of Use refer to the current website you are visiting (the “Website”). All access to and use of this Website is governed by these Terms of Use. Visiting and using this Website indicates that the user (either “user” or “you” in th … CIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATION OR EXCLUSION MAY NOT APPLY TO YOU. IN ADDITION, THE COMPANY SHALL NOT HAVE ANY LIABILITY TO ANY PERSON FOR ANY IN JURY OR LOSS (INCLUDING PERSONAL INJURY AND CONSEQUENTIAL LOSS) SUFFERED WHILE PARTICIPATING IN ANY TREATMENTS DESCRIBED OR REFERRED TO IN THE WEBSITE. THE MATERIAL IN THE WEBSITE IS GIVEN AS GENERAL INFORMATION ONLY AND THE COMPANY GIVES NO WARRANTY AS TO THE SAFETY AND SECURITY OF SUCH TREATMENTS. Indemn … Website in the form of questions, requests, user information, and other. If you submit information to Cerevance through this Website (e.g., the “Contact Us” webpage, via email, forms and/or questionnaires), all such information may be processed and utilized by Cerevance in accordance with the Privacy Policy and consistent with applicable laws and regulations. Cerevance shall have all appropriate use for the information without compensation to the user or visitor who provided … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Craig Thompson, CEO Placement at Cerevance About Insights Expertise Life Science Executive Search Deep Tech Executive Search Defense Tech Executive Search Biotech Executive Search Venture Capital Executive Search Our Work Case Studies Placements Contact Discuss An Executive Search Get Started Get Started Occam Places Craig Thompson as CEO at Cerevance Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, has brought on Craig Thompson as Chief Executive Officer. Craig brings over 25 years of commercial and marketing leadership ex
CVN293 About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact CVN293 NEURODEGENERATIVE DISORDERS Potentially a first in class, oral non-dopaminergic therapy for the broad treatment of the signs and symptoms (motor and non-motor) of Parkinson’s disease. Suppresses the NRLP3 inflammasome signaling and reduces production of proinflammatory cytokines in the CNS, without effecting the peripheral immune response. NETSseq identified KCNK13 as a novel target in the microglia, without significant expression in peripheral immune cells, that regulates NLRP3 inflammasome activation. CVN293 t … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media June 16, 2022 Cerevance to Present During the 5th Annual LSX World Congress USA What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynami … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Cerevance About Pipeline NETS seq MEDIA CAREERS Log In Schedule a Demo Contact Back to media August 7, 2025 Cerevance to Participate in Piper Sandler Virtual CNS Symposium What’s a Rich Text element? The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. Static and dynamic content editing A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic … oral Sciences at Stanford University. Learn More May 3, 2017 Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance. Learn More December 2, 2016 Cerevance Launched Wit
Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor June 3, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Dr. Summers to help guide Cerevance’s Drug Discovery and Development Efforts June 3, 2019 14:17 UTC BOSTON--( BUSINESS WIRE )-- Cerevance , a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin